The above findings prompted us to further investigate in future studies the molecular mechanisms underlying the effect of ARHGAP35 on inhibiting the progression of GC such as the activation of the membrane-associated periodic skeleton or receptor tyrosine kinase pathways. Here, ARHGAP35 is linked to gastric cancer.